Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIK2AD)

Drug Name

OPC-64005 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Attention deficit hyperactivity disorder	6A05.Z	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Serotoninnorepinephrinedopamine reuptake (SNDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasotraline	DMLDQFV	Attention deficit hyperactivity disorder	6A05.Z	Approved	[3]
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[3]
Brilaroxazine	DM90J3J	Idiopathic pulmonary fibrosis	CB03.4	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serotoninnorepinephrinedopamine reuptake (SNDR)	TT8G3Z7	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03324581) The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Otsuka Pharmaceutical.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of Reviva Pharmaceuticals